| Literature DB >> 33182801 |
Saerom Kong1, Hye-Ryung Choi2,3, Yoon-Jeong Kim2, Yoon-Sik Lee1, Kyoung-Chan Park2,4, Seon-Yeong Kwak5,6.
Abstract
Excessive accumulation of melanin can cause skin pigmentation disorders, which may be accompanied by significant psychological stress. Although many natural and synthetic products have been developed for the regulation of melanogenesis biochemistry, the management of unwanted skin pigmentation remains challenging. Herein, we investigated the potential hypopigmenting properties of peptide sequences that originated from milk proteins such as ĸ-casein and β-lactoglobulin. These proteins are known to inhibit melanogenesis and their hydrolysates are reported as antioxidant peptides. We synthesize tetrapeptide fragments of the milk protein hydrolysates and investigate the amino acids that are essential for designing peptides with tyrosinase inhibitory and antioxidant activities. We found that the peptide methionine-histidine-isoleucine-arginine amide sufficiently inhibits mushroom tyrosinase activity, shows potent antioxidant activity and effectively impedes melanogenesis in cultured melanocytes via cooperative biological activities. Our findings demonstrate the potential utility of the bioactive tetrapeptide from milk proteins as a chemical alternative to hypopigmenting agents.Entities:
Keywords: antioxidant; hypopigmenting; milk-protein derived tetrapeptides; tyrosinase inhibitor
Year: 2020 PMID: 33182801 PMCID: PMC7698045 DOI: 10.3390/antiox9111106
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Milk protein-derived peptides and their tetrapeptide fragments.
| Source | Original Peptide Sequence | Tetrapeptide Fragments | ||
|---|---|---|---|---|
| κ-casein | YFYPEL | YFYP | FYPE | YPEL |
| β-lactoglobulin | YVEEL | YVEE | VEEL | YVEL |
| MHIRL | MHIR | HIRL | ||
| WYSLAMAA | WYSL | YSLA | SLAM | |
| LAMA | AMAA | |||
Note. Y = tyrosine; F = phenylalanine; P = proline; E = glutamic acid; L = leucine; V = valine; M = methionine; H = histidine; I = isoleucine; R = arginine; W = tryptophan; S = serine; A = alanine.
Figure 1Half-maximal inhibitory concentration (IC50) values of milk-derived peptides and their fragments. The dotted line indicates tetrapeptides under IC50 100 µM. Conditions: various concentrations of peptides, L-DOPA (2.5 mM) and mushroom tyrosinase (100 µg/mL, 428 U/mL) were incubated at 25 °C for 10 min.
Figure 2The effects of peptides (a) methionine-histidine-isoleucine-arginine amide (MHIR) and (b) histidine-isoleucine-arginine-leucine amide (HIRL) on dopachrome formation with L-DOPA and mushroom tyrosinase, (c) the mushroom tyrosinase inhibitory activities of MHIR, HIRL derivatives and kojic acid. The percent tyrosinase inhibition was determined after treating 100 μM of peptides or kojic acid with L-DOPA (2.5 mM) and mushroom tyrosinase (100 µg/mL, 428 U/mL) and incubating at 25 °C for 10 min. Each experiment was conducted in triplicate and the results were averaged. (d) Lineweaver-Burk plot of tyrosinase inhibition reaction in the presence of MHIR peptide at various concentrations.
Figure 3Relative antioxidant activities of peptides that are based on the percentage of lipid peroxidation inhibition after 24 h. The reaction was conducted at 50 °C under dark conditions. The final concentration of peptides was 250 μM. Each experiment was performed in triplicate and the values are presented as the mean ± standard error.
Figure 4Hypopigmenting activity of methionine-histidine-isoleucine-arginine-leucine (MHIRL) family peptides in melanocytes. The effects of MHIRL family on cell viability (a) in Mel-Ab cells and (b) in B16F10 cells. [peptide] = 100 μM. The melanogenesis inhibitory activities of the MHIRL family (c) in Mel-Ab cells and (d) in B16F10 cells. [peptide] = 100 μM. The melanogenesis inhibitory activities of MHIR (e) in Mel-Ab cells and (f) in B16F10 cells. (g) Remaining melanin contents (%) in α-MSH treated B16F10 cells with N-terminal acetylated MHIR (Ac-MHIR) at various concentrations. Each experiment was carried out in triplicate and the values are presented as the mean ± standard error.
Figure 5Effects of the MHIR peptide on melanogenesis-related signaling. α-MSH-treated B16F10 cells were incubated with MHIR (100 μM) for 0~360 min, after which the whole-cell lysates were analyzed via western blotting using specific antibodies. Equal protein loading was confirmed by probing for GAPDH expression. The relative quantities of phosphorylated CREB were normalized to that of total CREB. This graph is a representative result of three independent experiments.